Amedisys, Inc. (NASDAQ:AMED) Shares Acquired by Signaturefd LLC

Signaturefd LLC grew its stake in Amedisys, Inc. (NASDAQ:AMED) by 20.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,367 shares of the health services provider’s stock after purchasing an additional 236 shares during the quarter. Signaturefd LLC’s holdings in Amedisys were worth $132,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AMED. SG Americas Securities LLC boosted its position in Amedisys by 413.4% during the third quarter. SG Americas Securities LLC now owns 196,713 shares of the health services provider’s stock worth $18,985,000 after acquiring an additional 158,398 shares during the last quarter. Highbridge Capital Management LLC boosted its position in Amedisys by 34.7% during the second quarter. Highbridge Capital Management LLC now owns 323,200 shares of the health services provider’s stock worth $29,670,000 after acquiring an additional 83,200 shares during the last quarter. Murchinson Ltd. acquired a new position in Amedisys during the first quarter worth about $6,752,000. Calamos Advisors LLC boosted its position in Amedisys by 11.6% during the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider’s stock worth $36,476,000 after acquiring an additional 41,220 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in Amedisys by 61.0% during the second quarter. Canada Pension Plan Investment Board now owns 79,200 shares of the health services provider’s stock worth $7,271,000 after acquiring an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Trading Down 1.8 %

NASDAQ AMED opened at $95.49 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys, Inc. has a 52 week low of $89.55 and a 52 week high of $98.95. The stock has a market capitalization of $3.12 billion, a PE ratio of -149.20, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The firm has a 50 day moving average of $97.04 and a two-hundred day moving average of $95.58.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on AMED shares. Deutsche Bank Aktiengesellschaft lowered shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price on the stock. in a report on Monday, July 29th. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Finally, William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $100.67.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.